Результаты поиска - Utkarsh Goel
- Отображение 1 - 2 результаты of 2
-
1
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immun... по Danai Dima, Mariola A. Vazquez-Martinez, James A. Davis, Utkarsh Goel, Aimaz Afrough, Aishwarya Sannareddy, Oren Pasvolsky, Beatrice Razzo, Rahul Banerjee, Jack Khouri, Ariel Grajales-Cruz, Alex Lieberman-Cribbin, Masooma Shifa Rana, Kelley Julian, Shaun DeJarnette, Andrew J. Portuguese, Mahmoud R. Gaballa, Gabriel De Avila, Sandra Susaniba Adaniya, Shahzad Raza, Megan M. Herr, Evguenia Ouchveridze, Tiffany Richards, Hitomi Hosoya, Lekha Mikkilineni, Gurbakhash Kaur, Omar Castaneda Puglianini, Adriana Rossi, Yi Lin, Shebli Atrash, Douglas Sborov, Kenneth H. Shain, Peter M. Voorhees, Shambavi Richard, Alfred L. Garfall, Doris K. Hansen, Surbhi Sidana, Krina K. Patel, Andrew J. Cowan, Larry D. Anderson, Hans C. Lee, Faiz Anwer, Christopher J. Ferreri, Leyla Shune
Опубликовано 2025-06-01Abstract Data describing outcomes of teclistamab in multiple myeloma patients with prior exposure to BCMA-directed therapy (BCMA-DT) are limited. The goal of this multicenter retrospective analysis was to report the efficacy and safety of standard-of-care teclistamab in patients with prior BCMA-DT....
Полный текст
Статья -
2
Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment по Danai Dima, Aimaz Afrough, Utkarsh Goel, Ariel F. Grajales-Cruz, Jack Khouri, Kelley Julian, Oren Pasvolsky, Rahul Banerjee, Beatrice Razzo, Christopher J. Ferreri, Mariola A. Vazquez-Martinez, James A. Davis, Aishwarya Sannareddy, Omar Castaneda, Shahzad Raza, Andrew J. Portuguese, Mahmoud R. Gaballa, Masooma S. Rana, Alex Lieberman-Cribbin, Shaun DeJarnette, Rebecca Gonzalez, Anna Chen, Megan M. Herr, Lekha Mikkilineni, Hitomi Hosoya, Evguenia Ouchveridze, Gurbakhash Kaur, Adriana Rossi, Leyla Shune, Faiz Anwer, Yi Lin, Shambavi Richard, Douglas W. Sborov, Rachid C. Baz, Alfred L. Garfall, Hans C. Lee, Larry D. Anderson, Jr., Andrew J. Cowan, Krina K. Patel, Peter M. Voorhees, Surbhi Sidana, Doris K. Hansen, Shebli Atrash, Sandra P. Susanibar-Adaniya
Опубликовано 2025-07-01Abstract: Outcomes of bispecific antibodies in patients with renal impairment (RI) are not well characterized, given the exclusion of these patients from clinical trials. Herein, we evaluated patients with relapsed/refractory multiple myeloma and RI treated with standard-of-care teclistamab. RI was...
Полный текст
Статья